Market Snapshot:
Nanobiosensors are actually the sensors that consist of nanomaterials and it is noteworthy that these are not the advanced sensors that can identify movements and activities on a nanoscale. Nano biosensors are also referred to as nanotube-based sensors when they involve carbon nanotubes as augmentations of reaction specificity as well as efficiency, while biosensors are referred to as nanotube-based sensors and carriers as nanowire biosensors. Recent advancements in nanotechnology and modern electronic technology converge towards the creation of a new collection of biosensors called nano biosensors and have led to a new era in disease detection bionanotechnology.
Highlights from Nano Biosensors - Market Study
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
CAGR | 7.8% |
The key Players profiled in the report are Abbott Point of Care, Inc. (United States), F. HOFFMAN-LA ROCHE LTD. (Switzerland), Medtronic Inc. (United States), Universal Biosensors, Inc. (Australia), Siemens Ag (Germany), Lifescan, Inc. (United States), Lifesensors, Inc. (United States), Nova Biomedical Corporation (United States), Acon Laboratories, Inc. (United States) and Pharmaco-Kinesis Corporation (United States). Additionally, other players that are part of this comprehensive study are Bayer Healthcare Ag (Germany), Bio-Rad Laboratories, Inc. (United States), Biacore, Inc. (United States), Biosensors International Pte. Ltd. (Singapore), Ercon, Inc. (United States) and Sysmex Corporation (Japan).
Geographic Breakdown and Segment Analysis
The Global Nano Biosensors - market presents a comprehensive analysis of the Nano Biosensors - market by end-user/application (Biological Application {DNA Sensors, Immunosensors, Cell based Sensor, Point of care Sensors, bacteria sensors, others} and Environmental Application {Agricultural Monitoring, Ground Water Screening, Ocean Monitoring, Others}), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Nano Biosensors - industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest.
For instance, while the holds majority of market share of the Nano Biosensors - market
Analyst at AMA have segmented the market study of Global Nano Biosensors - market by Type, Application and Region.
Influencing Trend:
Technological Advancements in Nano Biosensors Technology
Market Growth Drivers:
Significant Advances in Technology over the Recent Years and Increasing Usage of Nano Biosensors in Various Application
Challenges:
Government Regulations regarding Long Certification as well as Approval Cycles and Lack of Awareness Regarding Nano Biosensors
Restraints:
High Costs Involved in Research & Development
Opportunities:
High-Growth Opportunities in Biodefense, as well as the Food Industry, Growing Demand from Emerging Market such as China, India and others and Rising Health Care Sector in Emerging Economies
Market Developments Activities:
In February 2019 - The iQ Group Global introduced the Saliva Glucose Biosensor. This innovative technology is one of the world's few non-invasive, saliva-based glucose tests for diabetes management that measures glucose in saliva rather than blood. The saliva-based glucose test is being developed to improve the quality of life for over 425 million people living with diabetes globally. Source: https://www.mordorintelligence.com/industry-reports/global-nano-biosensors-market-industry
In May 2020, San Diego-based Roswell Biotechnologies and nano innovator Imec collaborated to make the first molecular electronics biosensors chips commercially available in 2021.
Regulatory Insights:
All medical devices are subject to the general controls of the Federal Food Drug & Cosmetic (FD&C) Act. These controls, which are contained in Title 21 Code of Federal Regulations Part 800-1200 (21 CFR Parts 800-1200) (FD&C Act, 2010), are the baseline requirements for marketing, labeling, and monitoring the postmarket performance of all medical devices. Technically, the U.S. FDA does not “approve” medical devices; it “clears” them for sale. The U.S. FDA marketing clearance process for medical devices can be described in three steps (U.S. FDA, 2013):
The global nano biosensors market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
Key Target Audience
Nano Biosensors Companies, Manufacturing Companies, Research Organizations, Venture Capitalists, Private Equity Firms and Others